Presenters at the cutting-edge developments in MS session deliver the newest key findings of pivotal studies. At the session, we heard about a novel therapeutic involved in remyelination, pathways that inhibit remyelination, a genetic risk factor that may also target the cell functions in the central nervous system, and reduced adverse events with extended interval dosing of an approved disease-modifying therapy.
Read on for highlights from the #ACTRIMS2018 cutting edge developments in MS research session.
Gut microbiome, blood brain barrier, risk factors—these are all emerging concepts in MS. Scientists have immersed themselves in research in these areas because of the promise they hold in finding a cure for MS. In fact, in the past couple of decades, there has been a remarkable expansion of new treatments for MS, novel imaging techniques that allow for earlier and quicker diagnosis, and great new ideas that all started as an “emerging concept”. In this session, researchers present the new ideas/concepts that inform us about how MS works, factors involved in MS and new ways to measure and capture disease activity and treatment options for people with MS.
The research team is on site again for another year of reporting on the latest and hottest news presented at the annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2018. This year’s meeting is held in San Diego, California from February 1-3.
Themed, “Therapeutic Targets in MS: the Frontier and Future of Disease Modifying Therapy,”, the forum is packed with leading researchers/clinicians presenting on hot topics in the field. Emerging concepts in the pathology, risk factors and imaging tools are sure to be news-worthy. Sessions are also planned on different cells—lymphocytes, microglia, macrophages, astrocytes and oligodendrocytes—and what role they play in MS. Moreover, the session on cutting-edge developments with topics such as novel therapeutics, and genetic influences of MS are for sure to be of interest. For more information, visit the ACTRIMS Forum 2018 site.
Stay tuned for more updates on #ACTRIMS2018 over the next few days, both here on the blog and on Twitter at @Dr_KarenLee.